In subsequent studies, no degradation was observed with native mouse MTH1 and a lack of dose–response degradation was also observed in the B16F10 mouse melanoma cell line, indicating that mouse MTH1 may be inaccessible for aTAG applications. Here, NUDT1 is linked to melanoma.